Skip to main content
Premium Trial:

Request an Annual Quote

ILS, Stemina Partner on Toxicity Screening

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ILS and Stemina Biomarker Discovery today announced they will work together to advance Stemina's stem cell-based toxicology testing platform, beginning with devTOX, an all-human based screen for evaluating the toxicity of drugs and chemical compounds on human development.

The deal gives ILS exclusive rights to distribute Stemina's platform in North America. The firms will also collaborate on the development of other platforms for evaluating the safety of compounds, they said.

Financial terms of the deal were not disclosed.

DevTox is a metabolomics platform that uses human embryonic stem cells to analyze the effects that pharmaceuticals, chemicals, and formulations may have on embryos.

Based in Research Triangle Park, NC, ILS is a research organization that provides support to the toxicology, genetic and molecular, histopathology, environmental, and information science fields.

Madison, Wis.-based Stemina uses mass spectrometry-based metabolomics to analyze small molecules secreted by cells in response to drugs, chemical compounds, and other contaminants.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.